topic

Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes
Chunwan Lu, John D. Klement, Mohammed L. Ibrahim, Wei Xiao, Priscilla S. Redd, Asha Nayak-Kapoor, Gang Zhou, Kebin Liu

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 157; DOI: 10.1186/s40425-019-0635-8
Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma
Swati Gupta, Leena McCann, Yvonne G. Y. Chan, Edwin W. Lai, Wei Wei, Pok Fai Wong, James W. Smithy, Jodi Weidler, Brian Rhees, Michael Bates, Harriet M. Kluger, David L. Rimm

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 254; DOI: 10.1186/s40425-019-0731-9
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
Geoffrey T. Gibney, Omid Hamid, Jose Lutzky, Anthony J. Olszanski, Tara C. Mitchell, Thomas F. Gajewski, Bartosz Chmielowski, Brent A. Hanks, Yufan Zhao, Robert C. Newton, Janet Maleski, Lance Leopold, Jeffrey S. Weber

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 80; DOI: 10.1186/s40425-019-0562-8
Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity
Giuseppe Minniti, Dimitri Anzellini, Chiara Reverberi, Gian Carlo Antonini Cappellini, Luca Marchetti, Federico Bianciardi, Alessandro Bozzao, Mattia Osti, Pier Carlo Gentile, Vincenzo Esposito

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 102; DOI: 10.1186/s40425-019-0588-y
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Yixin Zhou, Zuan Lin, Xuanye Zhang, Chen Chen, Hongyun Zhao, Shaodong Hong, Li Zhang

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 120; DOI: 10.1186/s40425-019-0600-6
TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
Matthew J. Reilley, Brittany Morrow, Casey R. Ager, Arthur Liu, David S. Hong, Michael A. Curran

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 323; DOI: 10.1186/s40425-019-0811-x
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
Mathieu Grapin, Corentin Richard, Emeric Limagne, Romain Boidot, Véronique Morgand, Aurélie Bertaut, Valentin Derangere, Pierre-Antoine Laurent, Marion Thibaudin, Jean David Fumet, Gilles Crehange, François Ghiringhelli, Céline Mirjolet

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 160; DOI: 10.1186/s40425-019-0634-9
miR-448 targets IDO1 and regulates CD8⁺ T cell response in human colon cancer
Qiong Lou, Ruixian Liu, Xiangling Yang, Weiqian Li, Lanlan Huang, Lili Wei, Huiliu Tan, Nanlin Xiang, Kawo Chan, Junxiong Chen, Huanliang Liu

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 210; DOI: 10.1186/s40425-019-0691-0
The motility regulator flhDC drives intracellular accumulation and tumor colonization of Salmonella
Vishnu Raman, Nele Van Dessel, Owen M. O’Connor, Neil S. Forbes

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 44; DOI: 10.1186/s40425-018-0490-z
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
Andrew B. Nixon, Kurt A. Schalper, Ira Jacobs, Shobha Potluri, I-Ming Wang, Catherine Fleener

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 325; DOI: 10.1186/s40425-019-0799-2

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages